Albot Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Albot Technologies's estimated annual revenue is currently $1.1M per year.
- Albot Technologies's estimated revenue per employee is $50,750
Employee Data
- Albot Technologies has 21 Employees.
- Albot Technologies grew their employee count by -16% last year.
Albot Technologies's People
Name | Title | Email/Phone |
---|
Albot Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.7M | 92 | -4% | N/A | N/A |
#2 | $124.9M | 1205 | 24% | $177.6M | N/A |
#3 | $121.5M | 1172 | -3% | $250M | N/A |
#4 | $21.2M | 266 | 23% | N/A | N/A |
#5 | $46.2M | 510 | 27% | N/A | N/A |
#6 | $1207.7M | 11649 | 14% | $1.7B | N/A |
#7 | $312.7M | 3016 | 8% | $113.8M | N/A |
#8 | $6.8M | 94 | -24% | N/A | N/A |
#9 | $23.9M | 300 | -2% | N/A | N/A |
#10 | $307.7M | 3032 | 8% | N/A | N/A |
What Is Albot Technologies?
We at Albot strive towards innovations built to elevate the human experience by continuously adapting to the rapid growth of the world. We offer a wide range of advanced solutions and enable you to blend business needs with the latent unmet needs of the user. Our ingenious solutions span across the multiple domains of Healthcare, Technology, Artificial Intelligence, Cybersecurity, Nuclear Fusion, Biotech, Microbiome, Stem Cells, Acne and more.
keywords:N/AN/A
Total Funding
21
Number of Employees
$1.1M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Albot Technologies News
2022-04-06 - DY Patil University in Pune to conduct research in nuclear fusion technology
The DY Patil International University and Albot Technologies Private ... fusion technology under the project titled 'Project Sanlayan'.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.1M | 21 | N/A | $5M |
#2 | $1.1M | 21 | N/A | N/A |
#3 | $1.1M | 21 | N/A | N/A |
#4 | $1.1M | 21 | N/A | N/A |
#5 | N/A | 21 | 11% | N/A |